A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine

References

• GBD 2016. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease Study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• GBD 2016. Headache collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954–976.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–315.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015 Mar;55(Suppl 2):103–122.
   PubMedGoogle Scholar
• Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505–1518.
   PubMed Web of Science ®Google Scholar
• Zajdel P, Bednarski M, Sapa J, et al. Ergotamine and nicergoline - facts and myths. Pharmacol Rep. 2015;67(2):360–363.
   PubMedGoogle Scholar
• Eigenbrodt AK, Ashina H, Khan S, et al., Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 17(8): 501–514. 2021.
   PubMed Web of Science ®Google Scholar
• Lenaerts ME, JR C Jr. Treatment of headache following triptan failure after successful triptan therapy. Curr Treat Options Neurol. 2015;17(6):353.
   PubMedGoogle Scholar
• Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Primers. 2022;8(1):2.
   PubMed Web of Science ®Google Scholar
• Hou M, Liu H, Li Y, et al. Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. Eur J Clin Pharmacol. 2019;75(10):1369–1378.
   PubMedGoogle Scholar
• Ghanshani S, Chen C, Lin B, et al., Risk of acute myocardial infarction, heart failure, and death in migraine patients treated with triptans. Headache. 60(10): 2166–2175. 2020.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia. 2014;34(4):258–267.
   PubMed Web of Science ®Google Scholar
• Burch RC, Ailani J, Robbins MS. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2022;62(1):111–112.
   PubMedGoogle Scholar
• Lipton RB, Stewart WF, Stone AM, et al. Disability in strategies of care study group. Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) Study: a randomized trial. JAMA. 2000;284(20):2599–2605.
   PubMed Web of Science ®Google Scholar
• Vikelis M, Dermitzakis EV, Vlachos GS, et al. Open label prospective experience of supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 for episodic migraine prophylaxis. J Clin Med. 2020;10(1):67.
   Google Scholar
• Argyriou AA, Mitsikostas DD, Mantovani E, et al. Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. Expert Rev Neurother. 2021;21(8):923–944.
   PubMedGoogle Scholar
• Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.
   PubMed Web of Science ®Google Scholar
• Constantinidis TS, Arvaniti C, Fakas N, et al., A population-based survey for disabling headaches in Greece: prevalence, burden and treatment preferences. Cephalalgia. 41(7): 810–820. 2021.
   PubMedGoogle Scholar
• Deen M, Correnti E, Kamm K, et al. European headache federation school of advanced studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18(1):96.
   PubMed Web of Science ®Google Scholar
• Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(Pt 1):232–241.
   PubMedGoogle Scholar
• Maniyar FH, Sprenger T, Schankin C, et al. Photic hypersensitivity in the premonitory phase of migraine–a positron emission tomography study. Eur J Neurol. 2014;21(9):1178–1183.
   PubMed Web of Science ®Google Scholar
• Maniyar FH, Sprenger T, Schankin C, et al. The origin of nausea in migraine-a PET study. J Headache Pain. 2014;15(1):84.
   PubMedGoogle Scholar
• Coppola G, Di Renzo A, Tinelli E, et al. Thalamo-cortical network activity during spontaneous migraine attacks. Neurology. 2016;87(20):2154–2160.
   PubMedGoogle Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016;139(Pt 7):1987–1993.
   PubMedGoogle Scholar
• Amin FM, Hougaard A, Magon S, et al. Change in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study. Neurology. 2016;86(2):180–187.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen X, Liu M, et al. Altered functional connectivity of amygdala underlying the neuromechanism of migraine pathogenesis. J Headache Pain. 2017;18(1):7.
   PubMedGoogle Scholar
• Santangelo G, Russo A, Trojano L, et al. Cognitive dysfunctions and psychological symptoms in migraine without aura: a cross-sectional study. J Headache Pain. 2016;17(1):76.
   PubMedGoogle Scholar
• Lyubashina OA, Panteleev SS, Sokolov AY. Inhibitory effect of high-frequency greater occipital nerve electrical stimulation on trigeminovascular nociceptive processing in rats. J Neural Transm (Vienna). 2017;124(2):171–183.
   PubMedGoogle Scholar
• Johnston MM, Jordan SE, Charles AC. Pain referral patterns of the C1 to C3 nerves: implications for headache disorders. Ann Neurol. 2013;74(1):145–148.
   PubMedGoogle Scholar
• Viana M, Sances G, Ghiotto N, et al. Variability of the characteristics of a migraine attack within patients. Cephalalgia. 2016;36(9):825–830.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Baca SM, Vanvalkenburgh P, et al. Distinctive anatomical and physiological features of migraine aura revealed by 18 years of recording. Brain. 2013;136(Pt 12):3589–3595.
   PubMedGoogle Scholar
• Hartings JA, Shuttleworth CW, Kirov SA, et al. The continuum of spreading depolarizations in acute cortical lesion development: examining Leao’s legacy. J Cereb Blood Flow Metab. 2017;37(5):1571–1594.
   PubMed Web of Science ®Google Scholar
• Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–182.
   PubMed Web of Science ®Google Scholar
• Russo A, Tessitore A, Silvestro M, et al. Advanced visual network and cerebellar hyperresponsiveness to trigeminal nociception in migraine with aura. J Headache Pain. 2019;20(1):46.
   PubMedGoogle Scholar
• Tolner EA, Chen SP, Eikermann-Haerter K. Current understanding of cortical structure and function in migraine. Cephalalgia. 2019;39(13):1683–1699.
   PubMedGoogle Scholar
• Jacobs B, Dussor G. Neurovascular contributions to migraine: moving beyond vasodilation. Neuroscience. 2016;338:130–144.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The vascular theory of migraine-a great story wrecked by the facts. Brain. 2009;132(Pt 1):6–7.
   PubMedGoogle Scholar
• Shevel E. The extracranial vascular theory of migraine-a great story confirmed by the facts. Headache. 2011;51(3):409–417.
   PubMedGoogle Scholar
• Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33(13):1085–1095.
   PubMed Web of Science ®Google Scholar
• Edvinsson JCA, Haanes KA, Edvinsson L. Neuropeptides and the nodes of Ranvier in cranial headaches. Front Physiol. 2022;12:820037.
   PubMedGoogle Scholar
• Hay DL, Garelja ML, Poyner DR, et al. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br J Pharmacol. 2018;175(1):3–17.
   PubMed Web of Science ®Google Scholar
• Tringali G, Navarra P. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides. 2019;116:16–21.
   PubMedGoogle Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(2):47–55.
   PubMedGoogle Scholar
• Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 2010;75(17):1520–1526.
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.
   PubMed Web of Science ®Google Scholar
• Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018;58(3):238–275.
   PubMedGoogle Scholar
• Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–567.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Edvinsson L, Jakate A, et al. Pharmacology and pharmacokinetics of ubrogepant: a potent, selective calcitonin gene-related peptide receptor antagonist for the acute treatment of migraine. J Fam Pract. 2020;69(1 Suppl):S8–S12.
   PubMedGoogle Scholar
• Scott LJ. Ubrogepant: first approval. Drugs. 2020;80(3):323–328.
   PubMed Web of Science ®Google Scholar
• Jakate A, Boinpally R, Butler M, et al., Evaluation of the pharmacokinetic interaction of ubrogepant coadministered with sumatriptan and of the safety of ubrogepant with triptans. Headache. 60(7): 1340–1350. 2020.
   PubMedGoogle Scholar
• Croop R, Lipton RB, Kudrow D, et al., Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 397(10268): 51–60. 2021.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Rimegepant: first approval. Drugs. 2020;80(7):741–746.
   PubMed Web of Science ®Google Scholar
• Gao B, Yang Y, Wang Z, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol. 2020;10:1577.
   PubMed Web of Science ®Google Scholar
• DeFalco AP, Lazim R, Cope NE. Rimegepant orally disintegrating tablet for acute migraine treatment: a review. Ann Pharmacother. 2021;55(5):650–657.
   PubMedGoogle Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149.
   PubMed Web of Science ®Google Scholar
• Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180.
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Goadsby PJ, et al. ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695–706. 8
   PubMed Web of Science ®Google Scholar
• Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65–70.
   PubMed Web of Science ®Google Scholar
• Boinpally R, Jakate A, Butler M, et al. Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial. Pain Manag. 2021Dec13;12(4):499–508. Epub ahead of print.
   PubMedGoogle Scholar
• Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309–315.
   PubMed Web of Science ®Google Scholar
• Biohaven. https://www.biohavenpharma.com/investors/news-events/press-releases/02-04-2019. Accessed on 2022 Feb 25.
   Google Scholar
• Srinivasan K, Kozminski K, Zhang Y, et al. Pharmacological, pharmacokinetic, pharmacodynamic and physicochemical characterization of FE 205030: a potent, fast acting, injectable CGRP receptor antagonist for the treatment of acute episodic migraine. J Pharm Sci. 2022;111(1):247–261.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:71.
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan - a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
   PubMedGoogle Scholar
• Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(11):958–966.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ho AP, Ge YJ, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia. 2016;36(2):148–161.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Ailani J, et al., Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 19(9): 727–737. 2020.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ, Lipton RB, Ailani J, et al., Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 42(1): 3–11. 2022.
   PubMed Web of Science ®Google Scholar
• BIBN 4096 BS Clinical Proof of Concept Study Group, Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–1110.
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573–584.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31(6):712–722.
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, et al. MK-0974 protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304–1312.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al., Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 372(9656): 2115–2123. 2008.
   PubMed Web of Science ®Google Scholar
• Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73(12):970–977.
   PubMed Web of Science ®Google Scholar
• Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51(1):73–84.
   PubMed Web of Science ®Google Scholar
• Ho AP, Dahlöf CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30(12):1443–1457.
   PubMed Web of Science ®Google Scholar
• Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient’s historical triptan response. Headache. 2011;51(1):64–72.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Martin V, Lipton RB, et al. Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache. 2011;51(4):533–543.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ho AP, Chaitman BR, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012;52(2):224–235.
   PubMed Web of Science ®Google Scholar
• Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–898.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al., Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache. 60(4): 686–700. 2020.
   PubMedGoogle Scholar
• Blumenfeld AM, Goadsby PJ, Dodick DW, et al. Efficacy of ubrogepant based on prior exposure and response to triptans: a post hoc analysis. Headache. 2021;61(3):422–429.
   PubMedGoogle Scholar
• Blumenfeld AM, Knievel K, Manack Adams A, et al., Ubrogepant is safe and efficacious in participants taking concomitant preventive medication for migraine: a pooled analysis of phase 3 trials. Adv Ther. 39(1): 692–705. 2022.
   PubMedGoogle Scholar
• Goadsby PJ, Blumenfeld AM, Lipton RB, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications. Cephalalgia. 2021;41(5):546–560.
   PubMedGoogle Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–125.
   PubMed Web of Science ®Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al., Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 394(10200): 737–745. 2019.
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov. Efficacy and safety study of rimegepant for the preventative treatment of migraine in pediatric subjects. Available from https://www.clinicaltrials.gov/ct2/show/NCT05156398 cited 2022 Feb 15.
   Google Scholar
• clinicaltrials.gov. A study of galcanezumab (LY2951742) in adult participants with episodic migraine (CHALLENGE-MIG). Available from https://www.clinicaltrials.gov/ct2/show/NCT05127486 cited 2022 Feb 15
   Google Scholar
• clinicaltrials.gov. Efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine. Available from https://www.clinicaltrials.gov/ct2/show/NCT03855137 cited 2022 Feb 15.
   Google Scholar
• (ELEVATE)clinicaltrials.gov. Atogepant for prophylaxis of migraine in participants who failed previous oral prophylactic treatments. Available from https://www.clinicaltrials.gov/ct2/show/NCT04740827 Accessed on 2022 Feb 15.
   Google Scholar
• clinicaltrials.gov. A study to evaluate the efficacy and safety of oral zavegepant in migraine prevention. Available from https://www.clinicaltrials.gov/ct2/show/NCT04804033 Accessed on 2022 Feb 15.
   Google Scholar
• clinicaltrials.gov. Study to evaluate oral ubrogepant in the acute treatment of migraine during the prodrome in adult participants (UBR prodrome). Available from https://www.clinicaltrials.gov/ct2/show/NCT04492020 Accessed on 2022 Feb 15.
   Google Scholar
• clinicaltrials.gov. Evaluation of the efficacy of almotriptan and ubrogepant for the acute treatment of migraine (ATOM). Available from https://www.clinicaltrials.gov/ct2/show/NCT05214001 Accessed on 2022 Feb 15.
   Google Scholar
• clinicaltrials.gov. Study to assess adverse events and disease activity of oral ubrogepant tablets for the acute treatment of migraine in children and adolescents (Ages 6-17). Available from https://www.clinicaltrials.gov/ct2/show/NCT05125302 Accessed on 2022 Feb 15
   Google Scholar
• clinicaltrials.gov. Safety and efficacy trial of BHV3000 (rimegepant) 75 mg for the acute treatment of migraine. Available from https://www.clinicaltrials.gov/ct2/show/NCT04574362 Accessed on 2022 Feb 15
   Google Scholar
• clinicaltrialsregister.eu. A randomized, parallel-group, single-attack, open-label study to evaluate the efficacy of diclofenac potassium and rimegepant for the acute treatment of migraine (ATOM). Available from https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001057-31 Accessed on 2022 Feb 15
   Google Scholar
• clinicaltrials.gov. Randomized study in children and adolescents with migraine: acute treatment. Available from https://www.clinicaltrials.gov/ct2/show/NCT04649242 Accessed on 2022 Feb 15.
   Google Scholar
• VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021;325(23):2357–2369.
   PubMed Web of Science ®Google Scholar
• Jakate A, Blumenfeld AM, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642–652.
   PubMed Web of Science ®Google Scholar
• Diener HC, Ashina M, Durand-Zaleski I, et al. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the international headache society. Cephalalgia. 2021;41(3):279–293.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Mitsikostas DD, Mantovani E, et al. An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management. Expert Rev Neurother. 2021;21(4):475–490.
   PubMed Web of Science ®Google Scholar
• Ferreira KS, Dhillon H, Velly AM. The role of a potential biomarker in patients with migraine: review and new insights. Expert Rev Neurother. 2021;21(7):817–831.
   PubMedGoogle Scholar